High-Risk Mitral Valve Surgery: Perioperative Hemodynamic Optimization with Nesiritide (BNP)
Sacha P. Salzberg, Farzan Filsoufi, Anelechi Anyanwu, Kai von Harbou, Alan Gass, Sean P. Pinney, Alain Carpentier and David H. Adams
Nesiritide is a recombinant brain-type natriuretic peptide (BNP), which decreases pulmonary arterial (PA) pressures and myocardial oxygen consumption while increasing coronary flow and urine output. Mitral valve (MV) surgery in patients with severe mitralregurgitation (MR), impaired left ventricular function, and pulmonary hypertension is associated with a high operative mortality. We hypothesized that the perioperative use of Nesiritide is safe, and may improve surgical outcomes.
Perioperative use of Nesiritide is safe, and may contribute to improved early outcomes in high-risk patients undergoing MV surgery. This may be due to improved ventricular loading conditions (decreased PA pressures, more effective diuresis) and/or a direct myocardial effect of BNP. Further prospective evaluation of the role of BNP in cardiac surgery is warranted.
Share
Publications
-
Failure to Rescue: A Quality Metric for Cardiac Surgery and Cardiovascular Critical Care
Caroline R Gross, David H Adams, Parth Patel, Robin Varghese -
In memoriam: Randall B. Griepp (1940-2022)
David H Adams, Dimosthenis Pandis -
Transcatheter Repair for Patients with Tricuspid Regurgitation
Paul Sorajja, MD, Brian Whisenant, MD, David H. Adams, MD, et al. -
Outcomes of Simultaneous Heart and Kidney Transplantation
Shinobu Itagaki, Nana Toyoda, Noah Moss, Donna Mancini, Natalia Egorova, Takahisa Mikami, Erick Sun, Yuki Bekki, Gregory Serrao, Anuradha Lala, Percy Boateng, David H Adams, Anelechi C Anyanwu